The biotech bubble bursting has created more affordable options for the corporate venture capital (VC) arms of major pharma companies to provide support to innovative start-ups in need of development know-how, regulatory help and cash
A Guiding Hand For Biotech Start-Ups In Turbulent Times
Rising Leader Therese Liechtenstein is playing an integral part in the creation and financing of multiple companies in the M Ventures portfolio, guiding them towards key value inflection points that a potential partner or acquirer would like to see.
